Bone mineral density and blood pressure in patients with asymptomatic hyperparathyroidism. The Tromsù Study
|
|
- Merryl Knight
- 5 years ago
- Views:
Transcription
1 Journal of Internal Medicine 2000; 247: 325±330 Bone mineral density and blood pressure in patients with asymptomatic hyperparathyroidism. The Tromsù Study R. JORDE 1,3 & J. SUNDSFJORD 2 From the Departments of 1 Internal Medicine and 2 Clinical Chemistry, University Hospital of Tromsù, Tromsù, Norway, and 3 Centre for Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, University of Newcastle, Newcastle, Australia Abstract. Jorde R, Sundsfjord J (University Hospital of Tromsù, Tromsù, Norway). Bone mineral density and blood pressure in patients with asymptomatic hyperparathyroidism. The Tromsù Study. J Intern Med 2000; 247: 325±330. Objective. To evaluate bone mineral density and blood pressure in asymptomatic hyperparathyroidism. Design. A case-control study. Setting. The participants obtained from an epidemiological survey in Tromsù 1994±95, that included more than subjects. The reexamination in 1998 was performed at the University Hospital of Tromsù, Norway. Participants. Thirty-nine subjects with hyperparathyroidism and 72 control subjects were studied. Main outcome measures. Bone mineral density measurements of the lumbar spine and the proximal femur (femoral neck, Ward's triangle, and trochanter). Systolic and diastolic blood pressure. Results. In the hyperparathyroidism group bone mineral density was significantly lower measured at the lumbar spine ( vs g cm 22, mean 6 SD, P, 0.01) and at the femoral neck ( vs g cm 22, P, 0.05). In the females, but not in the males, blood pressure was significantly higher in the hyperparathyroidism group than in the control group [systolic blood pressure vs mmhg (P, 0.05) and diastolic blood pressure vs mmhg (P, 0.05)]. In the females the number of subjects on antihypertensive medication was significantly higher in the hyperparathyroidism group than in the control group (32.1% and 16.6%, respectively, P, 0.01). Conclusions. Subjects with asymptomatic hyperparathyroidism have moderately reduced bone mineral density. In females with hyperparathyroidism there is an increase in blood pressure. Keywords: blood pressure, bone mineral density, hypertension, primary hyperparathyroidism. Introduction Bone disease and hypertension have traditionally been associated with hyperparathyroidism. Originally, bone disease in the form of osteitis fibrosa cystica was a common part of the disease presentation [1], whereas today this is seldom seen. On the other hand, several recent studies have shown a reduced bone mineral density in patients with hyperparathyroidism [2±4], and measurement of bone density has been recommended as part of the clinical evaluation before deciding upon surgical treatment [5]. Similarly, hypertension is a well known part of hyperparathyroidism [6±8]. However, the cause of hypertension in hyperparathyroidism is uncertain, and there appears to be no effect of surgery on the blood pressure [9, 10]. Most studies on hyperparathyroidism have been performed on patients diagnosed because of specific clinical symptoms, or discovered by chance through multichannel biochemical screening where hyperparathyroidism originally was not suspected. Only a few are based on epidemiological studies [11], and therefore cohorts of patients with truly asymptomatic hyperparathyroidism are rare. In Tromsù, Northern Norway, there have been four large health surveys since In the last one in 1994±95, serum calcium was measured in all subjects, and those with a value above 2.59 mmol L 21 were re-examined. Those fulfilling our criteria for hyperparathyroidism were re-exam- # 2000 Blackwell Science Ltd 325
2 326 R. JORDE & J. SUNDSFJORD ined every year, and if clinically indicated, surgery was recommended. Thus a group of subjects with asymptomatic hyperparathyroidism was established, suitable for examining the presence of reduced bone density as well as hypertension in the mild form of the disease. Materials and methods Subjects A total of men and women were included in the Tromsù study in 1994±95. All subjects had blood samples drawn for serum calcium measurements. If the serum calcium was greater than 2.59 mmol L 21, and the subject was below the age of 76 and living within reasonable distance from the city centre, the subject was asked to come for new blood samples for measurement of serum calcium, creatinine, and parathyroid hormone. In order to include subjects with mild hyperparathyroidism, a diagnosis of hyperparathyroidism was made if serum calcium was greater than 2.49 mmol L 21 and serum parathyroid hormone greater than 5.9 pmol L 21 ; or serum calcium was greater than 2.54 mmol L 21 and serum parathyroid hormone greater than 5.4 pmol L 21 ; or serum calcium was greater than 2.59 mmol L 21 and serum parathyroid hormone greater than 4.9 pmol L 21, provided the serum creatinine was below 150 mmol L 21. Subjects fulfilling these criteria were then re-examined annually at the outpatient clinic at the Medical Department, University Hospital of Tromsù. If the serum calcium was above 2.80 mmol L 21, and/or the patient had symptoms that could be ascribed to hypercalcaemia, operation was advised. In 1998 the subjects with hyperparathyroidism were invited to have a bone mineral density measurement in addition to the routine follow-up. An age- and sex-matched control group of 72 subjects was recruited from the cohort that in 1994/95 had a serum calcium level lower than 2.60 mmol L 21. Subjects using oestrogen or bisphosphonates were not included in the control group. Measurements The follow-up study was performed at the Clinical Research Unit at the University Hospital of Tromsù. After a general health examination a medical history was taken and present medication recorded. All subjects filled out a questionnaire on dietary habits that included questions on consumption of milk, cheese, yoghurt, bread, butter, and fat fish. Furthermore, they were asked for daily use of calcium and vitamin D tablets, and cod liver oil supplementation. Using a Norwegian food table [12] the daily intake of calcium and vitamin D from these products was calculated. Height and weight were measured in light clothing without shoes. Body mass index was calculated as weight in kilograms divided by the square of the height in meters. Blood pressure was measured with an automatic device (Propaq S/W version 6.0; Protocol systems, Beaverton, Oregon, USA). The subjects were seated for 5 min before the first of three measurements, 1 min apart. The mean of the two last measurements was used in the analysis. The subjects were not requested to fast. Bone mineral density was measured using a Lunar DPX-L dual-energy X-ray absorptiometer (Lunar Radiation Corporation, Madison, Wisconsin, USA). Separated scans for the lumbar spine in the posteroanterior (L1±L4) projection and the proximal femur (femoral neck, Ward's triangle, and trochanter) were carried out and analysed with the manufacturer's software version 1.3. Blood samples were drawn and analysed for serum calcium, phosphate, creatinine, albumin, and ALP on Hitachi 917 with reagents from Boehringer Mannheim (Mannheim, FRG). Serum ionized calcium was measured with an ion-selective electrode (Ciba Corning 288; Chiron Diagnostics Corporation, USA). The measurements were carried out in serum samples collected anaerobically, and the samples were centrifuged and analysed within 1 h. The actual measured serum ionized calcium levels, without ph adjustments, were used. Intact parathyroid hormone was measured on Immulite (Diagnostic Products Corporation, Los Angeles, USA) based on a two-site chemiluminescent immunocompetitive assay. Statistical analyses Comparisons between the subjects with hyperparathyroidism and the control group were made using the Student's t-test. For bone mineral density and blood pressure the groups were in addition com-
3 BMD AND BP IN PATIENTS WITH HPT 327 pared using linear regression with bone mineral density or blood pressure as dependent variable and body mass index and age as covariables. A comparison of the number of subjects on antihypertensive medication in the two groups was made using the x 2 -test. With regard to blood pressure, possible interactions between hyperparathyroidism or control group status, use of antihypertensive medication, and gender were tested with linear regression using blood pressure as a dependent variable and the other variables in question as fixed factors. Possible associations between blood pressure and bone mineral density were tested with linear regression using blood pressure as a dependent variable, the same fixed factors as above, and bone mineral density, age and body mass index as independent variables. All tests were performed two-sided, and P, 0.05 was considered statistically significant; the data are presented as mean 6 SD. Statistical analyses were carried out using SPSS version 8.0 (SPSS Inc., Chicago). Ethics The study was approved by the Regional Ethics Committee, and all subjects gave their written informed consent to participate. Results Subjects A total of 366 subjects had serum calcium above 2.59 mmol L 21. Of these, 282 subjects had a second set of blood samples. One subjects was diagnosed with gastric cancer, 217 had normal serum calcium and parathyroid hormone levels, and 64 fulfilled our criteria for hyperparathyroidism. Surgery was performed in eight, and three subjects died during the follow-up period. Of the remaining 53 subjects, one had moved, nine dropped out during the follow-up period, and four did not want to participate in the present examination. Thus, 39 subjects (11 males) with hyperparathyroidism attended the extended examination in None of them were using oestrogen substitution or were taking bisphosphonates. The characteristics of the two study groups appear from Table 1; the sex distribution was almost identical, but the hyperparathyroidism group had a slightly lower mean age. The hyperparathyroidism Table 1 Characteristics of the hyperparathyroidism (HPT) group and the control group and results of the examinations (mean SD) Normal range HPT group Control group Males/females 11/28 18/54 Age (years) Serum calcium (mmol L 21 ) 2.20± c Serum ionized calcium (mmol L 21 ) 1.10± c Serum PTH (pmol L 21 ) 1.1±6.8 f c Serum phosphate (mmol L 21 ) 0.75± c Serum albumin (g L -1 ) 35.0± Serum alkaline phosphatase (U L 21 ) 80±275 g c Serum creatinine (mmol L 21 ) 70±120 h BMI (kg m 22 ) Calcium intake (mg day 21 ) Vitamin D intake (mg day 21 ) Bone mineral density (g cm 22 ) Lumbar spine ae Femoral neck d Ward's triangle Trochanter Systolic blood pressure (mm Hg) Diastolic blood pressure (mm Hg) a P < 0.05; 2 P < 0.01; c P < vs. control group (Student's t-test). d P < 0.05; e P < 0.01 vs. control group (linear regression). f >50 years: 1.1±7.5; g >70 years: 100±400; h Females: 55±100.
4 328 R. JORDE & J. SUNDSFJORD group had significantly higher (P, 0.001) serum total calcium, ionized calcium, parathyroid hormone, and serum alkaline phosphatase (ALP). There were no significant differences regarding serum levels of creatinine and albumin, nor for the intakes of calcium and vitamin D. Body mass index was nonsignificantly higher in the hyperparathyroidism group. Bone mineral density The bone mineral density measured at the lumbar spine was significantly lower in the hyperparathyroidism group than in the control group (P, 0.05). When controlling for age and body mass index this was also seen for the femoral neck (P, 0.05; Table 1). When looking at men and women separately, the differences in bone mineral density between the hyperparathyroidism and the control group were present in both sexes. However, it reached statistical significance only for the females (Table 2). Blood pressure Both the systolic and diastolic blood pressure were higher in the hyperparathyroidism group, but for both sexes taken together the differences were not statistically significant (Table 1). However, in this regard males and females behaved differently. Thus, for the males, the blood pressure was slightly lower in those with hyperparathyroidism, whereas in the females it was significantly higher (P, 0.05) in the hyperparathyroidism group, both for systolic and diastolic blood pressure (Table 2). There was a difference in use of blood pressure medication in the two groups; 14 of the 39 subjects with hyperparathyroidism (35.9%) used blood pressure medication, whereas this was the case in only 14 of the 72 controls (19.4%; P, 0.01). For males separately the corresponding figures were five out of 11 subjects with hyperparathyroidism (45.5%), and five out of 18 in the control group (27.8%) (NS). In the females the figures were nine out of 28 in the hyperparathyroidism group (32.1%), and nine out of 54 in the control group (16.6%) (P, 0.01). If excluding those on blood pressure medication, there was still a difference in blood pressure between females with hyperparathyroidism and the control group, but the difference did not reach statistical significance (Table 2). Regarding blood pressure, there were no significant interactions between gender, hyperparathyroidism or control group, and use of antihypertensive medication; neither was there any significant association with bone mineral density. Discussion In the present study we looked at a group of subjects with hyperparathyroidism that were recruited from an epidemiological survey. When diagnosed by us, Table 2 Bone mineral density (BMD) and blood pressure (BP) in relation to gender in the hyperparathyroidism (HPT) group and the control group (mean SD) Males Females HPT group Control group HPT group Control group Number of subjects Bone mineral density (g cm 22 ) Lumbar spine ac Femoral neck b Ward's triangle b Trochanter Systolic BP (mm Hg) b Diastolic BP (mm Hg) ab Subjects not on medication for BP Number of subjects Systolic BP (mm Hg) Diastolic BP (mm Hg) a P < 0.05 vs. control group (Student's t-test); b P < 0.05 and c P < 0.01 vs. control group (linear regression).
5 BMD AND BP IN PATIENTS WITH HPT 329 none of them were aware they had hypercalcaemia. Those with symptoms that could be ascribed to hyperparathyroidism, or those with serum calcium persistently above 2.80 mmol L 21, were referred to surgery. The others were followed for 3 to 4 years before the present follow-up, and it is therefore fair to say that our patients were as asymptomatic as a clinical study group can be. Furthermore, our definition of hyperparathyroidism, which was similar to that used by Lundgren et al. [13], included subjects with combinations of serum calcium and serum parathyroid hormone in the upper normal range. Most of our patients therefore had a very mild form of the disease, which was documented by their mean serum calcium being only 2.56 mmol L 21 at the present follow-up. In this respect our hyperparathyroidism subjects differ from those previously reported, where the patients with hyperparathyroidism have frequently been recruited from those referred to surgical treatment [4, 14, 15]. It was remarkable that out of the 282 subjects that had a second set of blood samples, hyperparathyroidism was only confirmed in 64. However, it must be recalled that our subjects were recruited from an epidemiological survey, and the number of `false positive tests' is therefore bound to be large when the cut off was set as low as 2.60 mmol L 21. Our control group was well matched to those with hyperparathyroidism. However, the hyperparathyroidism group was slightly younger and had a slightly higher body mass index than the controls, which could affect both the bone mineral density and the blood pressure. Therefore, this was controlled for in the statistical analysis. Furthermore, the groups were similar regarding intake of calcium and vitamin D, although the calcium intake was lower than expected (probably due to the food frequency questionnaire mainly covering dairy products and not fully including the dinner meal). None of the subjects were taking drugs for the treatment of osteoporosis, but considerably more of those with hyperparathyroidism were on medication for hypertension. However, this could not increase the difference between the groups with regard to blood pressure. Accordingly, our study groups were well suited for disclosing differences regarding bone mineral density and blood pressure. As expected, we did find a reduced bone mineral density in the subjects with hyperparathyroidism; this was seen in both sexes, but most pronounced in the females. Depending on sex and site of measurement the difference between the two groups was from 3.5% to 10.2%. As the effect of parathyroid hormone has traditionally been claimed to be most profound on cortical bone [16] it was somewhat surprising that the difference was largest for the lumbar spine, which in contrast to the femoral neck has more cancellous than cortical bone. The reduction in bone mineral density has repeatedly been described in subjects with hyperparathyroidism [2±4, 17, 18]. Generally, the effect of parathyroid hormone on the skeleton is to increase both bone resorption and bone formation, and, as in other studies [4, 15], we found an increased serum ALP level in the hyperparathyroidism group, reflecting increased bone turn-over. In our study blood pressure was higher in those with hyperparathyroidism, but surprisingly, the difference was only seen in females, being 10 mmhg higher for the systolic and 6 mmhg higher for the diastolic blood pressure. This sex difference has, to our knowledge, not been commented on before. Furthermore in our study, far more subjects with hyperparathyroidism than controls had been diagnosed as hypertensive and were taking drugs to reduce the blood pressure. Accordingly, without medication the difference between the two groups would have been even greater. There are several previous reports on an increased blood pressure in patients with hyperparathyroidism [6±8, 10]. However, there does not appear to be a clear cause and effect relationship between hyperparathyroidism and hypertension. Thus, in the study by Salahudeen et al. [9], parathyroidectomy did not result in any change in blood pressure when the subjects were restudied half a year after surgery. Similarly, in a study by Lind et al. [10], mild hyperparathyroidism was associated with increased blood pressure, both in subjects that were left unoperated as well as in those successfully treated surgically. The apparent lack of effect of surgery on hypertension in hyperparathyroidism is puzzling. It could indicated that the development of hypertension is unrelated to hypercalcaemia or to the increased parathyroid hormone levels, and is instead caused by an as yet unknown factor. Another explanation could be that the hyperparathyroidism is diagnosed and treated too late. Most likely, as the disease process is very slow [19], subjects with
6 330 R. JORDE & J. SUNDSFJORD hyperparathyroidism have had the disease for years before diagnosis, which might have initiated an irreversible process leading to manifest hypertension. In hypertensive subjects an increased urinary calcium loss has been described [20]. If this applies to patients with hyperparathyroidism and hypertension as well, it could, at least in theory, add to the effect of hyperparathyroidism on the loss of calcium from the skeleton. However, in our study we did not find any inverse relation between hypertension and bone mineral density. In conclusion, subjects with asymptomatic hyperparathyroidism have moderately reduced bone mineral density. In females, but not in males, there is also an increased blood pressure. Acknowledgements The study was supported by a grant from The Norwegian Research Council. The assistance by the staff, in particular Annika Gustafsson, at the Clinical Research Unit, University Hospital of Tromsù, is gratefully acknowledged. References 1 Albright F, Aub JC, Bauer W. Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen cases from one clinic. JAMA 1934; 102: 1276± McDermott MT, Perloff JJ, Kidd GS. Effects of mild asymptomatic primary hyperparathyroidism on bone mass in women with and without estrogen replacement therapy. J Bone Miner Res 1994; 9: 509±14. 3 Gou C-Y, Thomas WEG, Al-Dehaimi AW, Assiri AMA, Eastell R. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 3487±91. 4 Christiansen P, Steiniche T, Brixen K, et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 1997; 21: 93±9. 5 NIH, Consensus Conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 1991; 114: 593±7. 6 HellstroÈm J, Birke G, Edvall CA. Hypertension in hyperparathyroidism. Br J Urol 1958; 30: 13±24. 7 Rosenthal FD, Roy S. Hypertension, hyperparathyroidism. Br Med J 1972; 4: 396±7. 8 Lind L, Hvarfner A, PalmeÂr M, Grimelius L, AÊ kerstroèm G, Ljunghall S. Hypertension in primary hyperparathyroidism in relation to histopathology. Eur J Surg 1991; 157: 457±9. 9 Salahudeen AK, Thomas TH, Sellars L, et al. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci 1989; 76: 289± Lind L, Jacobsson S, PalmeÂr M, Lithell H, Wengle B, Ljunghall S. Cardiovascular risk factors in primary hyperparathyroidism: a 15-year follow-up of operated and unoperated cases. J Intern Med 1991; 230: 29± PalmeÂr M, Adami H-O, BergstroÈm R, Jakobsson S, AÊ kerstroèm G, Ljunghall S. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet 1987; i: 59± Rimestad AH, Blaker B, FlaÊten A-M, Nordbotten A. Statens ernñringsraêd. Den Store Matvaretabellen. Oslo: Universitetsforlaget, Lundgren E, Rastad J, Thurfjell E, AÊ kerstroèm G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997; 121: 287± Martin P, Bergmann P, Gillet C, et al. Partially reversible osteopenia after surgery for primary hyperparathyroidism. Arch Intern Med 1986; 146: 689± Pfeilschifter J, Siegrist E, WuÈster C, Blind E, Ziegler R. Serum levels of intact parathyroid hormone and alkaline phosphatase correlate with cortical and trabecular bone loss in primary hyperparathyroidism. Acta Endocrinol 1992; 127: 319± Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW. Characterization and evaluation of asymptomatic primary hyperparathyroidism. J Bone Miner Res 1991; 6: S85±9. 17 Block MA, Dailey GE, Muchmore DE. Bone demineralization, a factor of increasing significance in the management of primary hyperparathyroidism. Surgery 1989; 106: 1063±8. 18 Hesp R, Tellez M, Davidson L, Elton A, Reeve J. Trabecular and cortical bone in the radii of women with parathyroid adenoma: a greater trabecular deficit, with a preliminary assessment of recovery after parathyroidectomy. Bone Miner 1987; 2: 301± Corlew DS, Bryda SL, Bradley EL, DiGirolamo M. Observations on the course of untreated primary hyperparathyroidism. Surgery 1985; 98: 1064± Young EW, Morris CD, McCarron DA. Urinary calcium excretion in essential hypertension. J Lab Clin Med 1992; 120: 624±32. Received 3 March 1999; accepted 14 September Correspondence: Dr R. Jorde, Department of Internal Medicine, University Hospital of Tromsù, 9038 Tromsù, Norway (fax: ; medrj@rito.no).
ORIGINAL INVESTIGATION. Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women
ORIGINAL INVESTIGATION Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism Four-Year Follow-up and Comparison With Healthy Postmenopausal
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Primary Hyperparathyroidism
Southern Derbyshire Shared Care Pathology Guidelines Primary Hyperparathyroidism Please use this Guideline in Conjunction with the Hypercalcaemia Guideline Definition Driven by hyperfunction of one or
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationEffects of surgery on outcome of primary hyperparathyroidism
1 Effects of surgery on outcome of primary hyperparathyroidism Peter Vestergaard Leif Mosekilde Peer Christiansen Introduction Primary hyperparathyroidism is a disease with effects on many organ systems
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More information"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy
"Asymptomatic" Hyperparathyroidism: Reasons for Parathyroidectomy Rebecca S. Sippel, M.D. Assistant Professor Department of Surgery Section of Endocrine Surgery University of Wisconsin Primary Hyperparathyroidism
More informationRadiographic Appearance Of Primary Hyperparathyroidism With Atypical Parathyroid Adenoma
ISPUB.COM The Internet Journal of Internal Medicine Volume 6 Number 2 Radiographic Appearance Of Primary Hyperparathyroidism With Atypical Parathyroid Adenoma P George, N Philip, B Pawar Citation P George,
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationORIGINAL ARTICLE. Severity, Clinical Significance, Relationship to Primary Hyperparathyroidism, and Response to Parathyroidectomy
ORIGINAL ARTICLE Osteoporosis in Multiple Endocrine Neoplasia Type Severity, Clinical Significance, Relationship to Primary Hyperparathyroidism, and Response to Parathyroidectomy John R. Burgess, MD, FRACP;
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationPrimary hyperparathyroidism is mild disease worth treating?
CONFERENCE SUMMARIES Clinical Medicine 2010, Vol 10, No 1: 45 9 Primary hyperparathyroidism is mild disease worth treating? NJL Gittoes and MS Cooper ABSTRACT Most patients with primary hyperparathyroidism
More informationShon E. Meek, M.D., Ph.D. Assistant Professor of Medicine
Shon E. Meek, M.D., Ph.D. Assistant Professor of Medicine meek.shon@mayo.edu 2016 MFMER 3561772-1 Update on Vitamin D Shon Meek MD, PhD 20 th Annual Endocrine Update January 30-Feb 3, 2017 Disclosure Relevant
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationHypercalcemia. Hypercalcemia: When to Worry, When to Treat! Mineral Metabolism : A Short Course
Hypercalcemia: When to Worry, When to Treat! Michael A. Levine has no financial relationships to disclose or Conflicts of Interest to resolve. Michael A. Levine, M.D. This presentation will not involve
More informationPRIMARY HYPERPARATHYROIDISM PRIMARY HYPERPARATHYROIDISM. Hyperparathyroidism Etiology. Common Complex Insidious Chronic Global Only cure is surgery
ENDOCRINE DISORDER PRIMARY HYPERPARATHYROIDISM Roseann P. Velez, DNP, FNP Francis J. Velez, MD, FACS Common Complex Insidious Chronic Global Only cure is surgery HYPERPARATHYROIDISM PARATHRYOID GLANDS
More informationElena Castellano, Roberto Attanasio, Laura Gianotti, Flora Cesario, Francesco Tassone, and Giorgio Borretta
ORIGINAL ARTICLE Forearm DXA Increases the Rate of Patients With Asymptomatic Primary Hyperparathyroidism Meeting Surgical Criteria Elena Castellano, Roberto Attanasio, Laura Gianotti, Flora Cesario, Francesco
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationName of Policy: Boniva (Ibandronate Sodium) Infusion
Name of Policy: Boniva (Ibandronate Sodium) Infusion Policy #: 266 Latest Review Date: April 2010 Category: Pharmacology Policy Grade: Active Policy but no longer scheduled for regular literature reviews
More informationApproach to a patient with hypercalcemia
Approach to a patient with hypercalcemia Ana-Maria Chindris, MD Division of Endocrinology Mayo Clinic Florida 2013 MFMER slide-1 Background Hypercalcemia is a problem frequently encountered in clinical
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 341 O CTOBER 21, 1999 NUMBER 17 A 10-YEAR PROSPECTIVE STUDY OF PRIMARY HYPERPARATHYROIDISM WITH OR WITHOUT
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationORIGINAL ARTICLE. Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism
Persistent Parathyroid Hormone Elevation Following Curative Parathyroidectomy for Primary Hyperparathyroidism Elizabeth A. Mittendorf, MD; Christopher R. McHenry, MD ORIGINAL ARTICLE Background: Persistent
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationMOST PATIENTS WITH primary hyperparathyroidism
0013-7227/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(3):1174 1178 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/jc.2002-020667 Raloxifene Lowers Serum Calcium
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationIndex. B BMC. See Bone mineral content BMD. See Bone mineral density Bone anabolic impact, Bone mass acquisition
A Acid base balance dietary protein detrimental effects of, 19 Acid base balance bicarbonate effects, 176 in bone human studies, 174 mechanisms, 173 174 in muscle aging, 174 175 alkali supplementation
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationPersistent post transplant hyperparathyroidism. Shiva Seyrafian IUMS-97/10/18-8/1/2019
Persistent post transplant hyperparathyroidism Shiva Seyrafian IUMS-97/10/18-8/1/2019 normal weight =18-160 mg In HPT= 500-1000 mg 2 Epidemiology Mild 2 nd hyperparathyroidism (HPT) resolve after renal
More informationNIH Public Access Author Manuscript Osteoporos Int. Author manuscript; available in PMC 2011 January 8.
NIH Public Access Author Manuscript Published in final edited form as: Osteoporos Int. 2011 January ; 22(1): 345 349. doi:10.1007/s00198-010-1179-4. Does Dietary Protein Reduce Hip Fracture Risk in Elders?
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationCases in Endocrinology
Bones, Moans and Groans Diagnosing and Treating Primary Hyperparathyroidism By M. Usman Chaudhry, MD Table 1 Laboratory parameters Her bone density had osteopenic T-Scores of -2.3 at lumbar spine, and
More informationCKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow
CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationAsymptomatic Primary Hyperparathyroidism
The new england journal of medicine clinical practice Asymptomatic Primary Hyperparathyroidism John P. Bilezikian, M.D., and Shonni J. Silverberg, M.D. This Journal feature begins with a case vignette
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationResearch Article Primary Hyperparathyroidism: 11-Year Experience in a Single Institute in Thailand
International Endocrinology Volume 2012, Article ID 952426, 4 pages doi:10.1155/2012/952426 Research Article Primary Hyperparathyroidism: 11-Year Experience in a Single Institute in Thailand Poramaporn
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More information9 Quality Assurance in Bone Densitometry section
9 Quality Assurance in Bone Densitometry section Introduction Bone densitometry is frequently used to determine an individual's fracture risk at a particular point in time but may also be used to assess
More informationMagnesium Homeostasis
ECTS PhD Training Course, Rome 3 rd September 2008 Disorders of Calcium, Phosphate h and Magnesium Homeostasis Richard Eastell Professor of Bone Metabolism Academic Unit of Bone Metabolism University of
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationAwaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page
f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationUCLA Nutrition Bytes. Title. Permalink. Journal ISSN. Author. Publication Date. Calcium and Hypertension. https://escholarship.org/uc/item/68b658ss
UCLA Nutrition Bytes Title Calcium and Hypertension Permalink https://escholarship.org/uc/item/68b658ss Journal Nutrition Bytes, 4(2) ISSN 1548-601X Author Martinez, Christina Publication Date 1998-01-01
More informationBone Disease after Kidney Transplantation
Bone Disease after Kidney Transplantation BTS March 2018 Dr Arif Khwaja PhD, FRCP Sheffield Kidney Institute Clinical case 47 year old female FSGS DBD 2007 egfr 25mls/min. Sirolimus, Azathioprine and prednisolone
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationHyperparathyroidism. When to Suspect, How to Diagnose, When and How to Intervene. Johanna A. Pallotta, MD, FACP, FACE
Hyperparathyroidism When to Suspect, How to Diagnose, When and How to Intervene Johanna A. Pallotta, MD, FACP, FACE Potential conflicts of interest: None Johanna A. Pallotta, MD Outline Definition of hyperparathyroidism
More informationIperparatiroidismo normocalcemico: vero o falso?
Iperparatiroidismo normocalcemico: vero o falso? Bari, 7-10 novembre 2013 TERAPIA E FOLLOW-UP A. Piovesan SCDU Endocrinologia Oncologica AO Città della Salute e della Scienza Molinette Torino THE THIRD
More informationPREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL
PREVALENCE AND PATTERNS OF HYPERPARATHYROIDISM AND MINERAL BONE DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AT KENYATTA NATIONAL HOSPITAL DR. ANNE MUGERA The Problem Chronic Kidney disease is a worldwide
More informationhypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause
hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationBone and Renal Stone Disease in Patients Operated for Primary Hyperparathyroidism in Pakistan: Is the Pattern of Disease different from the West?
ecommons@aku Section of Urology Department of Surgery August 1999 Bone and Renal Stone Disease in Patients Operated for Primary Hyperparathyroidism in Pakistan: Is the Pattern of Disease different from
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationPrevalence of Osteoporosis p. 262 Consequences of Osteoporosis p. 263 Risk Factors for Osteoporosis p. 264 Attainment of Peak Bone Density p.
Dedication Preface Acknowledgments Continuing Education An Introduction to Conventions in Densitometry p. 1 Densitometry as a Quantitative Measurement Technique p. 2 Accuracy and Precision p. 2 The Skeleton
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationDISUSE OSTEOPOROSIS IN PATIENTS WITH POLIOMYELITIS
DISUSE OSTEOPOROSIS IN PATIENTS WITH POLIOMYELITIS Jülide Öncü,MD Istanbul Sisli Etfal Teaching Hospital julideoncu@sislietfalgov.tr Arzu On,MD; Simin Hepguler,MD Ege University Medical Faculty arzuon@ege.edu.tr
More informationSince the advent of multichannel serum chemistry
ONLINE EXCLUSIVE Padmaja Sanapureddy, MD; Vishnu Vardhan Garla, MD; Mallikarjuna Reddy Pabbidi, DVM, PhD Department of Primary Care and Medicine, G.V. (Sonny) Montgomery VA Medical Center, Jackson, Miss
More informationBone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?
Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPrimary Hyperparathyroidism: A Tale of Two Cities Revisited New York and Shanghai
ORIGINAL ARTICLE Bone Research (2013) 2: 162-169. www.boneresearch.org Primary Hyperparathyroidism: A Tale of Two Cities Revisited New York and Shanghai Jian-min Liu 1, Natalie E. Cusano 2, Barbara C.
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More information9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy
The Impact of Dietary Protein on the Musculoskeletal System Outline A. The musculoskeletal system and associated disorders Jessica D Bihuniak, PhD, RD Assistant Professor of Clinical Nutrition Department
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationAnnie WC Kung, Keith DK Luk, LW Chu, and Peter KY Chiu
Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitropic hormones to dietary calcium deprivation 1 3 Annie WC Kung, Keith DK Luk, LW Chu, and
More informationUPDATES ON PRIMARY HYPERPARATHYROIDISM. Natalie E. Cusano, MD, MS Director, Bone Metabolism Program Lenox Hill Hospital New York, NY
UPDATES ON PRIMARY HYPERPARATHYROIDISM Natalie E. Cusano, MD, MS Director, Bone Metabolism Program Lenox Hill Hospital New York, NY Disclosures Speaker (Honorarium): Shire Off-label use of estrogen, raloxifene
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More information4/20/2015. The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy. Learning Objectives
The Neck xt Exploration: Intraoperative Parathyroid Hormone (IOPTH) Testing During Surgical Parathyroidectomy Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationSecondary Hyperparathyroidism: Where are we now?
Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused
More informationSummary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century
Summary Statement from a Workshop on Asymptomatic Primary Hyperparathyroidism: A Perspective for the 21st Century John P. Bilezikian, John T. Potts, Jr., Ghada El-Hajj Fuleihan, Michael Kleerekoper, Robert
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationCLINICAL STUDIES. Survival after the Diagnosis of Hyperparathyroidism: A Population-based Study*
CLINICAL STUDIES Survival after the Diagnosis of Hyperparathyroidism: A Population-based Study* Robert A. Wermers, MD, Sundeep Khosla, MD, Elizabeth J. Atkinson, MS, Clive S. Grant, MD, Stephen F. Hodgson,
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationPRIMARY HYPERPARATHYROIDISM
PRIMARY HYPERPARATHYROIDISM HYPERPARATHYROIDISM Inappropriate excess secretion of Parathyroid Hormone in Primary Hyperparathyroidism Appropriate Hypersecretion in Secondary Hyperparathyroidism PTH and
More informationDietary Protein and Bone Health Emphasis: Animal Protein
USDA-ARS Human Nutrition Research Centers Dietary Protein and Bone Health Emphasis: Animal Protein Z.K. (Fariba) Roughead, PhD, RD Research Nutritionist USDA-ARS Grand Forks Human Nutrition Research Center
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationCase Report A Reference Finding Rarely Seen in Primary Hyperparathyroidism: Brown Tumor
Case Reports in Medicine Volume 2012, Article ID 432676, 4 pages doi:10.1155/2012/432676 Case Report A Reference Finding Rarely Seen in Primary Hyperparathyroidism: Brown Tumor F. Mantar, 1 S. Gunduz,
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF NEW MEDICINAL PRODUCTS IN THE TREATMENT OF PRIMARY OSTEOPOROSIS
European Medicines Agency Evaluation of Medicines for Human Use London, 14 December 2005 Doc. Ref. CPMP/EWP/552/95 Rev. 2 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE EVALUATION
More information